Medical Marijuana’s (OTCMKTS:MJNA) Investment Company, AXIM Files Patent For Face Mask That Can Trap SARS-CoV-2 Particles

Medical Marijuana Inc. (OTCMKTS:MJNA) has announced that AXIM® Biotechnologies, its investment arm, has filed a provisional patent for the world’s first face mask that can capture and deactivate SARS-CoV-2.

AXIM® develops facemask that can trap effectively SARS-CoV-2

Stuart Titus, the CEO of Medical marijuana, said that demand for face masks has grown significantly due to the pandemic, and the market could reach $21.2 billion by 2026. This is because research has continued to support the ability of masks to reduce infection risk. He added that the AXIM® mask will be revolutionary and could be used in any environment and thus help the world in slowing the spread of the coronavirus. Titus said that medical marijuana was proud to support such an innovative venture in coming up with creative solutions to address current needs.

Most masks that are commercially available cannot filter tiny particles containing the virus efficiently. The virus attaches to the filtering material and if the mask is most its can penetrate and thus increasing infection risk. However, the AXIM® mask has been designed to offer increased protection by capturing viruses in the filter layer of the mask. The Mask employs novel reagents embedded in the masks to capture SARS-CoV-2 instantaneously. So far, early lab tests have shown that the SARS-CoV-2 spike protein binds tightly to the reagents that are interposed through the mask mesh.

AXIM is currently examining regulatory pathways required to receive approval for distributing the mask in the US through EPA or FDA and in the EU. The company will license face mask manufacturers to produce the masks in bulk while it manufactures the reagent ingredients.

Medical Marijuana attains stability testing milestone for RSHO-X™

Recently Medical Marijuana announced the achievement of a 2-year stability testing milestone on the flagship THC-free CBD oil Rea Scientific Hemp Oil-X™ (RSHO-X™). This study was conducted under strict compliance with FDA/ICH guidelines. The company outsourced the study to a qualified cGMP/cGLP-compliant Contract Research Organisation with ISO 17025 certification and accreditation.

Related Posts

About The Author

Add Comment